Should I buy or sell Avalo Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avalo Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AVTX shares. View AVTX analyst ratings or view top-rated stocks .

How have AVTX shares performed in 2024?

Avalo Therapeutics' stock was trading at $9.10 on January 1st, 2024. Since then, AVTX shares have increased by 27.8% and is now trading at $11.63. View the best growth stocks for 2024 here .

Are investors shorting Avalo Therapeutics?

Avalo Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 78,500 shares, an increase of 16.8% from the March 15th total of 67,200 shares. Based on an average trading volume of 642,100 shares, the days-to-cover ratio is presently 0.1 days. View Avalo Therapeutics' Short Interest .

When is Avalo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our AVTX earnings forecast .

How were Avalo Therapeutics' earnings last quarter?

Avalo Therapeutics, Inc. (NASDAQ:AVTX) announced its quarterly earnings data on Wednesday, March, 2nd. The company reported ($460.80) earnings per share for the quarter, missing analysts' consensus estimates of ($432.00) by $28.80. Avalo Therapeutics had a negative trailing twelve-month return on equity of 1,439.87% and a negative net margin of 1,639.50%.

When did Avalo Therapeutics' stock split?

Shares of Avalo Therapeutics reverse split on Friday, December 29th 2023. The 1-240 reverse split was announced on Friday, December 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

How do I buy shares of Avalo Therapeutics?

Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AVTX

Avalo Therapeutics (AVTX) Stock Price, News & Analysis

→ The only accurate crypto trading system I know … (From Weiss Ratings) (Ad)

Free AVTX Stock Alerts

$11.63

-0.38 (-3.16%)

(As of 04/19/2024 ET)

Compare

Today's Range: $11.50
▼
$13.02
50-Day Range: $4.20
▼
$21.75
52-Week Range: $3.95
▼
$1,130.40

Volume: 68,159 shs
Average Volume: 567,222 shs
Market Capitalization: $11.98 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Avalo Therapeutics alerts:

Avalo Therapeutics MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Bearish
7.62% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.64
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.91) to ($0.97) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.28 out of 5 stars

Medical Sector

884th out of 911 stocks

Pharmaceutical Preparations Industry

397th out of 411 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Avalo Therapeutics.

2.0

Short Interest

Percentage of Shares Shorted
7.62% of the outstanding shares of Avalo Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Avalo Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Avalo Therapeutics has recently increased by 16.82%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Avalo Therapeutics does not currently pay a dividend.
Dividend Growth
Avalo Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AVTX.

3.7

News and Social Media Coverage

News Sentiment
Avalo Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Avalo Therapeutics this week, compared to 1 article on an average week.
Search Interest
33 people have searched for AVTX on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.
MarketBeat Follows
8 people have added Avalo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Avalo Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.20% of the stock of Avalo Therapeutics is held by insiders.
Percentage Held by Institutions
87.06% of the stock of Avalo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Avalo Therapeutics are expected to decrease in the coming year, from ($0.91) to ($0.97) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Avalo Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Avalo Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Avalo Therapeutics has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Avalo Therapeutics Stock (NASDAQ:AVTX)

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

AVTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AVTX Stock News Headlines

April 17, 2024 | msn.com

Oppenheimer Upgrades Avalo Therapeutics (AVTX)

April 17, 2024 | msn.com

Avalo Therapeutics (AVTX) Price Target Increased by 4566.67% to 35.70

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

April 17, 2024 | americanbankingnews.com

Avalo Therapeutics (NASDAQ:AVTX) Upgraded to Outperform at Oppenheimer

April 2, 2024 | benzinga.com

Why VirTra Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

April 2, 2024 | globenewswire.com

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

March 29, 2024 | marketwatch.com

Avalo Therapeutics Shares More than Triple After Co Acquires AlmataBio

March 29, 2024 | globenewswire.com

Avalo Reports 2023 Financial Results and Provides Business Updates

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 29, 2024 | finanznachrichten.de

Avalo Therapeutics: Avalo Acquires Anti-IL-1ß mAb and Announces Private Placement Financing of up to $185 Million

March 28, 2024 | msn.com

Micro-Cap Avalo Therapeutics Stock Rallies As It Snaps AlmataBio For Ex-Eli Lilly Drug For Skin Disorder

March 28, 2024 | investorplace.com

Why Is Avalo Therapeutics (AVTX) Stock Up 326% Today?

March 27, 2024 | globenewswire.com

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

February 26, 2024 | finance.yahoo.com

Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?

January 2, 2024 | benzinga.com

Avalo Therapeutics Stock (NASDAQ:AVTX) Dividends: History, Yield and Dates

December 27, 2023 | msn.com

Avalo Therapeutics announces a 1-for-240 reverse stock split

December 27, 2023 | finance.yahoo.com

Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

December 18, 2023 | finance.yahoo.com

Avalo Therapeutics, Inc. (AVTX) stock forecast and price target

December 7, 2023 | finanznachrichten.de

Avalo Therapeutics: Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split

December 7, 2023 | finance.yahoo.com

Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split

November 11, 2023 | benzinga.com

Avalo Therapeutics Stock (NASDAQ:AVTX) Earnings Dates and Earning Calls

November 9, 2023 | morningstar.com

Avalo Therapeutics Inc AVTX

November 9, 2023 | finance.yahoo.com

Avalo Therapeutics Inc (AVTX) Announces Q3 2023 Financial Results and Strategic Advances

November 9, 2023 | finance.yahoo.com

Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

October 31, 2023 | finance.yahoo.com

Avalo Completes Divestiture of AVTX-800 Series

September 27, 2023 | finance.yahoo.com

BestGrowthStocks.com Issues a Comprehensive Analysis of Avalo Therapeutics

September 26, 2023 | benzinga.com

Why Avalo Therapeutics Stock Is Up Today

See More Headlines

Receive AVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/02/2022
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:AVTX
CUSIP: N/A
CIK: 1534120
Web: www.avalotx.com
Phone: (410) 522-8707
Fax: N/A
Employees: 19
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($616.6660)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-31,540,000.00
Net Margins: -1,639.50%
Pretax Margin: -1,638.77%
Return on Equity: -1,439.87%
Return on Assets: -113.95%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.82
Quick Ratio: 1.82

Sales & Book Value

Annual Sales: $1.92 million
Price / Sales: 6.24
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.11 per share
Price / Book: 1.28

Miscellaneous

Outstanding Shares: 1,030,000
Free Float: 1,032,000
Market Cap: $11.98 million
Optionable: Not Optionable
Beta: 1.15

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Garry A. Neil M.D. (Age 70)
Chairman of the Board, President & CEO
Comp: $475k
Mr. Christopher Ryan Sullivan (Age 40)
CFO & Head of Investor relations
Comp: $350k
Dr. Solomon H. Snyder M.D. (Age 85)
Founder and Chairman of Scientific Advisory Board
Dr. Barbara S. Slusher Ph.D. (Age 59)
Founder and Member of Scientific Advisory Board
Dr. Lisa Hegg Ph.D.
Senior Vice President of Program Management, Corporate Infrastructure & Clinical Operations
Ms. Colleen Matkowski
Senior Vice President of Global Regulatory Affairs & Quality Assurance
Dr. Dino C. Miano Ph.D.
Senior Vice President of CMC & Technical Operations

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

AVTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Avalo Therapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avalo Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AVTX shares.
View AVTX analyst ratings or view top-rated stocks.
How have AVTX shares performed in 2024?: Avalo Therapeutics' stock was trading at $9.10 on January 1st, 2024. Since then, AVTX shares have increased by 27.8% and is now trading at $11.63.
View the best growth stocks for 2024 here.
Are investors shorting Avalo Therapeutics?: Avalo Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 78,500 shares, an increase of 16.8% from the March 15th total of 67,200 shares. Based on an average trading volume of 642,100 shares, the days-to-cover ratio is presently 0.1 days.
View Avalo Therapeutics' Short Interest.
When is Avalo Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AVTX earnings forecast.

How were Avalo Therapeutics' earnings last quarter?: Avalo Therapeutics, Inc. (NASDAQ:AVTX) announced its quarterly earnings data on Wednesday, March, 2nd. The company reported ($460.80) earnings per share for the quarter, missing analysts' consensus estimates of ($432.00) by $28.80. Avalo Therapeutics had a negative trailing twelve-month return on equity of 1,439.87% and a negative net margin of 1,639.50%.
When did Avalo Therapeutics' stock split?: Shares of Avalo Therapeutics reverse split on Friday, December 29th 2023. The 1-240 reverse split was announced on Friday, December 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.
How do I buy shares of Avalo Therapeutics?: Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVTX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Avalo Therapeutics (AVTX) Stock Price, News & Analysis

Avalo Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Avalo Therapeutics Stock (NASDAQ:AVTX)

AVTX Stock Price History

AVTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

AVTX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™